Transcept Pharmaceuticals is a specialty pharmaceutical company dedicated to developing and commercializing proprietary products that address critical needs in the field of neuroscience. Intermezzo sublingual tablet C-IV is the company’s first FDA approved product and is currently in the stages of development and commercialization in the U.S. Transcept is presently conducting a phase 2 study of the investigational product TO-2061 in patients suffering from obsessive-compulsive disorder. For more information, visit the company’s Web site at www.transcept.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: